• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Proton Pump Inhibitors and Oncologic Treatment Efficacy: A Practical Review of the Literature for Oncologists.质子泵抑制剂与肿瘤治疗疗效：肿瘤学家文献的实用综述。
Curr Oncol. 2021 Feb 3;28(1):783-799. doi: 10.3390/curroncol28010076.
2
Drug-drug interactions with proton pump inhibitors in cancer patients: an underrecognized cause of treatment failure.癌症患者中质子泵抑制剂的药物相互作用：治疗失败的一个被低估的原因。
ESMO Open. 2023 Feb;8(1):100880. doi: 10.1016/j.esmoop.2023.100880. Epub 2023 Feb 8.
3
The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: Prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer.酪氨酸激酶抑制剂与质子泵抑制剂联合使用：老年癌症患者的流行率、预测因素以及对生存和治疗中断的影响。
Cancer. 2019 Apr 1;125(7):1155-1162. doi: 10.1002/cncr.31917. Epub 2019 Jan 3.
4
Interaction Between Low-Dose Methotrexate and Nonsteroidal Anti-inflammatory Drugs, Penicillins, and Proton Pump Inhibitors.低剂量甲氨蝶呤与非甾体抗炎药、青霉素及质子泵抑制剂之间的相互作用
Ann Pharmacother. 2017 Feb;51(2):163-178. doi: 10.1177/1060028016672035. Epub 2016 Oct 4.
5
Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study.基于一项观察性研究，质子泵抑制剂可能会降低转移性乳腺癌患者使用瑞博西利和哌柏西利的疗效。
BMC Cancer. 2022 May 7;22(1):516. doi: 10.1186/s12885-022-09624-y.
6
The Effect of Concomitant Proton Pump Inhibitor and Cabozantinib on the Outcomes of Patients with Metastatic Renal Cell Carcinoma.质子泵抑制剂与卡博替尼联合应用对转移性肾细胞癌患者结局的影响。
Oncologist. 2021 May;26(5):389-396. doi: 10.1002/onco.13711. Epub 2021 Feb 25.
7
Tyrosine Kinase Inhibitors and Proton Pump Inhibitors: An Evaluation of Treatment Options.酪氨酸激酶抑制剂与质子泵抑制剂：治疗方案评估
Clin Pharmacokinet. 2017 Jul;56(7):683-688. doi: 10.1007/s40262-016-0503-3.
8
Controversial link between proton pump inhibitors and anticancer agents: review of the literature.质子泵抑制剂与抗癌药物之间存在争议的联系：文献综述。
Tumori. 2022 Jun;108(3):204-212. doi: 10.1177/03008916211025091. Epub 2021 Jun 23.
9
Assessment of drug-drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer.在健康受试者和ALK阳性非小细胞肺癌患者中评估色瑞替尼与质子泵抑制剂之间的药物相互作用潜力。
Cancer Chemother Pharmacol. 2017 Jun;79(6):1119-1128. doi: 10.1007/s00280-017-3308-7. Epub 2017 Apr 19.
10
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients.帕博西尼与质子泵抑制剂之间的药物相互作用可能会显著影响转移性乳腺癌患者的临床结局。
ESMO Open. 2021 Oct;6(5):100231. doi: 10.1016/j.esmoop.2021.100231. Epub 2021 Sep 9.

引用本文的文献

1
Effect of Proton-Pump Inhibitor on Survival in Chinese Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer Receiving Upfront Combinatorial Docetaxel Treatment.质子泵抑制剂对接受一线多西他赛联合治疗的中国初治转移性激素敏感性前列腺癌患者生存的影响。
Cancers (Basel). 2025 Sep 1;17(17):2879. doi: 10.3390/cancers17172879.
2
Beyond the Basics: Exploring Pharmacokinetic Interactions and Safety in Tyrosine-Kinase Inhibitor Oral Therapy for Solid Tumors.基础之外：探索酪氨酸激酶抑制剂口服治疗实体瘤中的药代动力学相互作用及安全性
Pharmaceuticals (Basel). 2025 Jun 26;18(7):959. doi: 10.3390/ph18070959.
3
Proton pump inhibitors and all-cause mortality in colorectal cancer.质子泵抑制剂与结直肠癌的全因死亡率
Sci Rep. 2025 Jul 1;15(1):21315. doi: 10.1038/s41598-025-05570-4.
4
Potential drug-drug interactions among geriatric oncology patients: a retrospective study in Saudi Arabia.老年肿瘤患者中潜在的药物相互作用：沙特阿拉伯的一项回顾性研究。
BMC Geriatr. 2025 May 1;25(1):300. doi: 10.1186/s12877-025-05965-y.
5
Emerging Role of Extracellular pH in Tumor Microenvironment as a Therapeutic Target for Cancer Immunotherapy.细胞外 pH 值在肿瘤微环境中作为癌症免疫治疗的治疗靶点的新作用。
Cells. 2024 Nov 20;13(22):1924. doi: 10.3390/cells13221924.
6
Safety of solid oncology drugs in older patients: a narrative review.老年患者中固体肿瘤药物的安全性：叙述性综述。
ESMO Open. 2024 Nov;9(11):103965. doi: 10.1016/j.esmoop.2024.103965. Epub 2024 Oct 30.
7
Proton Pump Inhibitors Worsen Colorectal Cancer Outcomes in Patients Treated with Bevacizumab.质子泵抑制剂会恶化接受贝伐单抗治疗患者的结直肠癌治疗效果。
Cancers (Basel). 2024 Oct 2;16(19):3378. doi: 10.3390/cancers16193378.
8
The Effect of Concomitant Administration of Proton Pump Inhibitors on the Pharmacokinetics of CDK4/6 Inhibitors in Rats: Implications for the Evaluation of Hepatic and Transporter-Mediated Drug-Drug Interactions.质子泵抑制剂伴随给药对大鼠 CDK4/6 抑制剂药代动力学的影响：对肝和转运体介导的药物相互作用评价的启示。
Eur J Drug Metab Pharmacokinet. 2024 Sep;49(5):631-644. doi: 10.1007/s13318-024-00909-0. Epub 2024 Aug 6.
9
Estimation of CDK inhibitors by RP-HPLC: application for pharmacokinetic interactions studies with PPIs.用反相高效液相色谱法（RP-HPLC）估算细胞周期蛋白依赖性激酶抑制剂：在与质子泵抑制剂（PPIs）的药代动力学相互作用研究中的应用。
Bioanalysis. 2024;16(15):801-812. doi: 10.1080/17576180.2024.2372162. Epub 2024 Jul 17.
10
Playing Hide-and-Seek with Tyrosine Kinase Inhibitors: Can We Overcome Administration Challenges?与酪氨酸激酶抑制剂玩捉迷藏：我们能否克服给药挑战？
AAPS J. 2024 Jun 11;26(4):66. doi: 10.1208/s12248-024-00939-1.

本文引用的文献

1
Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials.抗生素和质子泵抑制剂治疗的非小细胞肺癌患者的化疗和阿特珠单抗疗效：OAK 和 POPLAR 试验的汇总事后分析。
Ann Oncol. 2020 Apr;31(4):525-531. doi: 10.1016/j.annonc.2020.01.006. Epub 2020 Jan 16.
2
Overall Survival with Osimertinib in Untreated, -Mutated Advanced NSCLC.奥希替尼治疗未经治、-突变型晚期 NSCLC 的总生存期。
N Engl J Med. 2020 Jan 2;382(1):41-50. doi: 10.1056/NEJMoa1913662. Epub 2019 Nov 21.
3
TRK inhibitors in TRK fusion-positive cancers.TRK 抑制剂在 TRK 融合阳性癌症中的应用。
Ann Oncol. 2019 Nov 1;30(Suppl_8):viii23-viii30. doi: 10.1093/annonc/mdz282.
4
FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced -Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management.美国食品药品监督管理局和欧洲药品管理局批准的晚期突变型非小细胞肺癌的酪氨酸激酶抑制剂：安全性、耐受性、血浆浓度监测和管理。
Biomolecules. 2019 Oct 30;9(11):668. doi: 10.3390/biom9110668.
5
Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication.哌柏西利和瑞博西尼治疗乳腺癌：合并用药管理共识研讨会
Ther Adv Med Oncol. 2019 May 10;11:1758835919833867. doi: 10.1177/1758835919833867. eCollection 2019.
6
Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAF mutation-positive metastatic melanoma treated with vemurafenib ± cobimetinib.接受维莫非尼±考比替尼治疗的 BRAF 突变阳性转移性黑色素瘤患者中，与酸还原剂同时给药和维莫非尼剂量对生存的影响。
Eur J Cancer. 2019 Jul;116:45-55. doi: 10.1016/j.ejca.2019.05.002. Epub 2019 Jun 4.
7
Lenvatinib, a molecule with versatile application: from preclinical evidence to future development in anti-cancer treatment.仑伐替尼，一种具有广泛应用的分子：从临床前证据到抗癌治疗的未来发展
Cancer Manag Res. 2019 May 1;11:3847-3860. doi: 10.2147/CMAR.S188316. eCollection 2019.
8
Impact of Concomitant Administration of Gastric Acid-Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials.胃抑酸剂与帕唑帕尼联合应用对 EORTC 62043/62072 试验软组织肉瘤患者治疗结局的影响。
Clin Cancer Res. 2019 Mar 1;25(5):1479-1485. doi: 10.1158/1078-0432.CCR-18-2748. Epub 2019 Feb 14.
9
Clinically relevant drug interactions with multikinase inhibitors: a review.多激酶抑制剂的临床相关药物相互作用：综述
Ther Adv Med Oncol. 2019 Jan 4;11:1758835918818347. doi: 10.1177/1758835918818347. eCollection 2019.
10
The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: Prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer.酪氨酸激酶抑制剂与质子泵抑制剂联合使用：老年癌症患者的流行率、预测因素以及对生存和治疗中断的影响。
Cancer. 2019 Apr 1;125(7):1155-1162. doi: 10.1002/cncr.31917. Epub 2019 Jan 3.

质子泵抑制剂与肿瘤治疗疗效：肿瘤学家文献的实用综述。

Proton Pump Inhibitors and Oncologic Treatment Efficacy: A Practical Review of the Literature for Oncologists.

机构信息

Centro Especializado em Oncologia, Hospital Alemão Oswaldo Cruz, São Paulo 01327-001, Brazil.

Centro Paulista de Oncologia, Grupo Oncoclínicas, São Paulo 04538-132, Brazil.

出版信息

Curr Oncol. 2021 Feb 3;28(1):783-799. doi: 10.3390/curroncol28010076.

DOI:10.3390/curroncol28010076
PMID:33546228
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7985775/
Abstract

Proton pump inhibitors (PPIs) are the most commonly used anti-acid drugs worldwide, including among cancer patients. However, drug-drug interactions between PPIs and other agents may lead to decreased drug absorption with possible reduced therapeutic benefit, or even increased toxicity. Unfortunately, only scarce data exist regarding the safety of concomitant PPI use with anti-cancer agents. We aim at reviewing current evidence on this possible interaction by dividing anti-cancer agents by class. Until further data is available, we encourage healthcare providers to limit unnecessary PPI overuse.

摘要

质子泵抑制剂（PPIs）是目前全球范围内应用最广泛的抗酸药物之一，包括癌症患者。然而，PPI 与其他药物之间的药物相互作用可能会导致药物吸收减少，从而降低治疗效果，甚至增加毒性。不幸的是，关于 PPI 与抗癌药物同时使用的安全性数据非常有限。我们旨在通过按类别划分抗癌药物来回顾当前关于这种可能的相互作用的证据。在获得更多数据之前，我们鼓励医疗保健提供者限制不必要的 PPI 过度使用。